Results 71 to 80 of about 65,667 (194)
Ajugol Improves Liver Fibrosis by Modulating Bile Acid and Arachidonic Acid Metabolism in Mice
Ajujol ameliorates hepatic fibrosis by regulating bile acid metabolism and suppressing inflammatory responses. ABSTRACT Ajugol (AJ), the primary component extracted from the root of Rehmannia glutinosa, exhibits protective effects against metabolic dysregulation and chronic inflammation.
Xia Wei +9 more
wiley +1 more source
Post-liver transplant intrahepatic cholestasis : etiology, clinical presentation, therapy [PDF]
Post-liver transplant intrahepatic cholestasis is consequent to the impairment of bile flow or formation. It may develop in the early (within 6 months) or in the late (more than 6 months) post-liver transplant period and different causes may be ...
V.M. Mazzaferro +8 more
core +2 more sources
Background: We conducted this study to investigate adverse pregnancy outcomes of hepatitis B virus infection coexistng with intrahepatic cholestasis in pregnant women, along with identifying associated risk factors.
Chong Zhang +3 more
doaj +1 more source
Benign recurrent intrahepatic cholestasis
Benign recurrent intrahepatic cholestasis (BRIC) is a rare cause of cholestasis in children. The disease may start in infancy or early childhood.
Bhatia, Baldev D +5 more
core +1 more source
Integrating cross‐cohort extracellular vesicle proteomics with machine learning identifies a simplified protein signature (AGT, FETUB, SPP2, and FCN3) for adverse pregnancy outcome risk stratification in systemic lupus erythematosus, enabling precise disease‐activity discrimination beyond routine clinical assessment.
Weiwei Shi +5 more
wiley +1 more source
Summary Mogamulizumab is a monoclonal antibody targeting CC‐chemokine receptor‐4 that is approved as a second‐line therapy for mycosis fungoides and Sézary syndrome. The most common adverse events include infusion‐related reactions and mogamulizumab‐associated rash.
Inga Hansen‐Abeck +6 more
wiley +1 more source
Benign recurrent intrahepatic cholestasis is an autosomal recessive disorder presenting with intermittent episodes of cholestatic jaundice. The initial episode of benign recurrent intrahepatic cholestasis tends to occur within the first two decades of a ...
Tafiya Erum Kamran +7 more
doaj +1 more source
IDO‐1 immunostaining identifies primary biliary cholangitis even in morphologically subtle bile duct lesions. IDO‐1 expression reflects cholangitis activity and is suppressed by ursodeoxycholic acid treatment, indicating its value as a dynamic diagnostic adjunct rather than a static marker of chronic damage.
Kaori Yoshimura +10 more
wiley +1 more source
Hepatobiliary transport systems mediate hepatic uptake and biliary excretion of bile acids, bilirubin and other biliary constituents. Hereditary or acquired defects of these transporters may cause or maintain cholestasis and jaundice under various ...
Martin Wagner, Michael Trauner
doaj +1 more source
ABSTRACT Aim In Fontan‐associated liver disease (FALD), chronic congestion often confounds conventional fibrosis markers, complicating surveillance for hepatocellular carcinoma (HCC). Although lymphatic dysfunction is fundamental to Fontan physiology, its contribution to hepatocarcinogenesis remains unclear.
Koji Imoto +14 more
wiley +1 more source

